S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.
Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Jhanelle E. Gray(Moffitt Cancer Center), Tawee Tanvetyanon(Moffitt Cancer Center), David R. Gandara(University of California, Davis), Mary W. Redman(Fred Hutch Cancer Center), Ying‐Qi Zhao(Fred Hutch Cancer Center), Janet Tu(The University of Texas MD Anderson Cancer Center), Barbara Ting-wen(NewYork–Presbyterian Hospital), Karen Kelly(Cancer Research Center), Jonathan W. Riess(University of California Davis Medical Center), Martin Joseph Edelman(Fox Chase Cancer Center), Ming-Hui Hsieh(Cancer Research And Biostatistics), Marianna Koczywas(City Of Hope National Medical Center)
Cited by 5
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k